Myrexis (MYRX) suspends development activity on all its programs, saying it's been unsuccessful to date in identifying and attracting third parties to whom it could out-license or sell assets for further development. In February, the company announced that it had suspended development activity on all of its preclinical and clinical programs, and retained Stifel Nicolaus Weisel to assist in reviewing and evaluating strategic alternatives.
Myrexis (MYRX) suspends development activity on all its programs, saying it's been unsuccessful...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs